Cargando…

The Graft-Versus-Leukemia Effect in AML

Allogeneic hematopoietic stem cell transplantation (allo-SCT) is the most established and commonly used cellular immunotherapy in cancer care. It is the most potent anti-leukemic therapy in patients with acute myeloid leukemia (AML) and is routinely used with curative intent in patients with interme...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sweeney, Connor, Vyas, Paresh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6877747/ https://www.ncbi.nlm.nih.gov/pubmed/31803612 http://dx.doi.org/10.3389/fonc.2019.01217

Ejemplares similares

Editorial: Acute myeloid leukemia (AML): Is it time for MRD-driven treatment?
por: Guolo, Fabio, et al.
Publicado: (2022)

A Predictor Combining Clinical and Genetic Factors for AML1-ETO Leukemia Patients
por: Yang, Min, et al.
Publicado: (2022)

Transient Abnormal Myelopoiesis and AML in Down Syndrome: an Update
por: Bhatnagar, Neha, et al.
Publicado: (2016)

Maintenance Therapy in AML
por: Reville, Patrick K., et al.
Publicado: (2021)

Development of Real-Time Quantitative Polymerase Chain Reaction Assays to Track Treatment Response in Retinoid Resistant Acute Promyelocytic Leukemia
por: Jovanovic, Jelena V., et al.
Publicado: (2011)

Clinical, Cytogenetic, and Molecular Findings in Two Cases of Variant t(8;21) Acute Myeloid Leukemia (AML)
por: Wilde, Lindsay, et al.
Publicado: (2019)

Intensified-Dose Chemotherapy in Combination With Gemtuzumab-Ozogamicin for the Treatment of Favorable-Risk Acute Myeloid Leukemia (AML)
por: Vegunta, Rathnamitreyee, et al.
Publicado: (2022)

MRD in AML: The Role of New Techniques
por: Voso, Maria Teresa, et al.
Publicado: (2019)

Targeting CXCR4 in AML and ALL
por: Cancilla, Daniel, et al.
Publicado: (2020)

Editorial: The Biological Landscape of Immunotherapy in AML
por: Isidori, Alessandro, et al.
Publicado: (2021)

Editorial: The latest advances in transplantation for AML
por: Chiusolo, Patrizia, et al.
Publicado: (2023)

Comparative analysis of extracellular vesicle isolation methods from human AML bone marrow cells and AML cell lines
por: Lang, Jonas B., et al.
Publicado: (2022)

Extracellular Vesicles and Chemotherapy Resistance in the AML Microenvironment
por: Nehrbas, Jill, et al.
Publicado: (2020)

Treatment of AML Relapse After Allo-HCT
por: Webster, Jonathan A., et al.
Publicado: (2021)

Maintenance therapy for AML after allogeneic HCT
por: Nayak, Rahul K., et al.
Publicado: (2022)

The Metabolic Signature of AML Cells Treated With Homoharringtonine
por: Zhang, Yulong, et al.
Publicado: (2022)

Towards a Better Understanding of Cohesin Mutations in AML
por: Cuartero, Sergi, et al.
Publicado: (2019)

Fatty Acid Metabolism, Bone Marrow Adipocytes, and AML
por: Tabe, Yoko, et al.
Publicado: (2020)

Cellular Metabolomics Profiles Associated With Drug Chemosensitivity in AML
por: Stockard, Bradley, et al.
Publicado: (2021)

Chimeric antigen receptor T-cell therapy for T-ALL and AML
por: Wei, Wenwen, et al.
Publicado: (2022)

Targeted therapy in NPM1-mutated AML: Knowns and unknowns
por: Wang, Rong, et al.
Publicado: (2022)

MRD in Venetoclax-Based Treatment for AML: Does it Really Matter?
por: Bernardi, Massimo, et al.
Publicado: (2022)

Editorial: Novel mechanisms for the treatment of AML before and after transplant
por: Kasner, Margaret T.
Publicado: (2022)

Optimizing Transplant Approaches and Post-Transplant Strategies for Patients With Acute Myeloid Leukemia
por: Loke, Justin, et al.
Publicado: (2021)

The Elephant in The Room: AML Relapse Post Allogeneic Hematopoietic Cell Transplantation
por: Abou Dalle, Iman, et al.
Publicado: (2022)

Analysis of Subset Chimerism for MRD-Detection and Pre-Emptive Treatment in AML
por: Georgi, Julia-Annabell, et al.
Publicado: (2022)

Identification of a Mitochondria-Related Gene Signature to Predict the Prognosis in AML
por: Jiang, Nan, et al.
Publicado: (2022)

Corneal perforation associated with ocular graft-versus-host disease
por: Xu, Yue, et al.
Publicado: (2022)

Caring for AML Patients During the COVID-19 Crisis: An American and Italian Experience
por: Wilde, Lindsay, et al.
Publicado: (2020)

MRD Tailored Therapy in AML: What We Have Learned So Far
por: Ngai, Lok Lam, et al.
Publicado: (2021)

Comparison of Multiple Clinical Testing Modalities for Assessment of NPM1-Mutant AML
por: Lopez, Amanda, et al.
Publicado: (2021)

FOXM1-AKT Positive Regulation Loop Provides Venetoclax Resistance in AML
por: Chesnokov, Mikhail S, et al.
Publicado: (2021)

Editorial: The Elephant in the Room: AML Relapse After Allogeneic Hematopoietic Cell Transplantation
por: Battipaglia, Giorgia, et al.
Publicado: (2022)

In quest for leukemia initiating cells in AML
por: De Grandis, Maria, et al.
Publicado: (2018)

Effect of He Plasma Jet Versus Surface Plasma on the Metabolites of Acute Myeloid Leukemia Cells
por: Xu, Dehui, et al.
Publicado: (2021)

An Overview of Targeted Therapies in Acute Myeloid Leukemia
por: Turkalj, Sven, et al.
Publicado: (2023)

Patterns of undertreatment among patients with acute myeloid leukemia (AML): considerations for patients eligible for non-intensive chemotherapy (NIC)
por: Hubscher, Elizabeth, et al.
Publicado: (2021)

Role of GFI1 in Epigenetic Regulation of MDS and AML Pathogenesis: Mechanisms and Therapeutic Implications
por: Möröy, Tarik, et al.
Publicado: (2019)

IDH1 as a Cooperating Mutation in AML Arising in the Context of Shwachman-Diamond Syndrome
por: Mourad, Stéphanie, et al.
Publicado: (2019)

The Interplay Between the Genetic and Immune Landscapes of AML: Mechanisms and Implications for Risk Stratification and Therapy
por: Mendez, Lourdes M., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_rit5k0s1fr57gokrsi503pdph5